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THE measurement of serum free thyroxine (FT4), which forms a small fraction
(0.01-0.05 per cent) of the circulating total thyroxine (TT4), might be expected to
provide the most accurate single biochemical index of thyroid status, on the basis
that only free hormone is bioavailable. The conventional estimation of FT4 by
equilibrium dialysis' is time consuming and the arrival of radioimmunoassay kits
suitable for routine clinical use has been eagerly awaited. We have assessed one such
kit (Amerlex free T4) incorporating an 1125 labelled thyroxine analogue and an anti-
thyroxine antibody which binds both the analogue and free, but not protein bound,
thyroxine. The competition for antibody binding sites between the known amount
of analogue and the unknown amount of free thyroxine allows measurement of the
free thyroxine. We have compared the clinical usefulness of FT4 measured by this
technique with that ofthe more traditional thyroid function tests (TT4 and a derived
free thyroxine index, FT4I).
PATIENTS AND METHODS
One hundred and one consecutive patients attending the thyroid clinic at the
Royal Victoria Hospital were studied. Ten were clinically hyperthyroid, six clinically
hypothyroid and the remaining 85 were clinically euthyroid, comprising previously
hypothyroid patients stabilized on thyroxine replacement, post-radioiodine follow
A grant has been made from the Royal Victoria Hospital Metabolic Unit Research Fund for the cost of
illustrations.
85up patients, hyperthyroid patients during a course ofantithyroid drug treatment and
patients with simple goitre. Patients on thyroxine had been instructed to take their
medication as a single dose in the morning. Fifty-two healthy euthyroid controls
(hospital staff and medical students), 23 euthyroid pregnant females (second and
third trimester) attending the Royal Maternity Hospital, and 10 hospital in-patients
with severe non-thyroidal illness (upper abdominal neoplasia, 2; hepatic failure due
to cirrhosis, 3; Crohn's disease, 1; renal failure, 1; chronic leukaemia, 1; cardiac
failure, 1) were also studied.
FT4, TT4 and FT4I were measured on mid afternoon serum samples and previous
treatment ofthyroid disease and current therapy were noted. Clinical thyroid status
at the time of the blood tests was assessed by one of the authors using standard
clinical techniques. Clinical hypothyroidism was confirmed by an elevated TSH
level, and all the patients with non-thyroidal illness had normal serum TSH.
Serum FT4 was measured using the Amerlex free T4 kit (Radiochemical Centre,
Amersham, UK). Serum TT4 was measured by radioimmunoassay using solid phase
thyroxine antiserum (Advanced Laboratory Techniques) and the free thyroxine
index was calculated from the ratio of TT4 to available thyroid hormone binding
sites measured by the uptake of 1 131 triiodothyronine (MAA kit, Amersham, UK).
The normal ranges (mean -i- 2 SD) for FT4 (14.8-26.4pmol/l), TT4 (72-134 nmol/l),
and FT4I (67-127), were derived from the control group in the present study.
RESULTS
A comparison ofthe mean values for each test is shown in Table 1. The individual
data for the three assay systems are illustrated in Figures 1-3. All three tests gave
appropriately high or low values in clinically hyper- or hypothyroid patients. FT4
values in hyperthyroid patients were more clearly separated from normal controls
than were TT4 and FT4I values.
TABLE 1
Results of3 thyroid hormone tests (mean± S.E.M.)
EIJEHYROID EUTHYROID
ON NOT ON NON-THYROIDAL
CONTROLS HYPERTHYROID HYPOTHYROID THYROXINE THYRtOXINE PREGNANT ILLNESS
(n = 52) (n = 10) (n = 6) (n = 32) (n = 53) (n = 23) (n = 10)
TOTAL THYROXINE 104 217 33 108o 85 140b 54d
(nmol/ ) + 2 + 21 + 4 +5 + 3 + 6 + 7
FREE THYROXINE 97 258 27 i9 75 105 56d
INDEX +2 +29 +3 +5 +3 +5 +6
FREE THYROXINE 20.5 83.6 5.2 24.20 18.1 13.0 12.4d
(pmoI/I) +0.4 +11.7 +0.6 +1.7 +0.8 +0.6 +1.5
a ON THYROXINE >NOT ON THYROXINE p<0.001
b PREGNANT>CONTROLS p<0.001
c PREGNANT <CONTROLS p<0.001
d NON-THYROIDAL ILLNESS< CONTROLS p<0.001
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FIGURE 1
Free thyroxine values. Patients on thyroxinedenotedby (0). Horizontalbroken lines
indicate limits ofnormal range.
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FIGURE 2
Total thyroxine. Patients on thyroxine denoted by (0). Horizontal broken lines
indicate limits ofnormal range.
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FIGURE 3
Free thyroxine index. Patients on thyroxine denoted by (0). Horizontal broken lines
indicate limits ofnormal range.
89FT4 in 32 euthyroid patients on thyroxine therapy (mean daily dosage 0.13 mg)
was significantly higher than in 53 euthyroid patients not on thyroxine, and also
higher than in controls: 9 of these 32 patients had FT4 values in the hyperthyroid
range (mean daily dosage 0.16 mg) and in five, FT4 was grossly elevated. In the 32
euthyroid patients on thyroxine, mean TT4 and FT4I were also higher than in the 53
patients not on thyroxine, but were not significantly different from the 52 controls.
Only five patients on thyroxine had TT4 values in the hyperthyroid range, while six
had FT4I values in the hyperthyroid range.
In euthyroid pregnancy FT4 was lower and TT4 was higher than in controls. FT4I
values were similar in the pregnant and non-pregnant states.
In severe non-thyroidal illness mean values of all tests (FT4, TT4, and FT4J) were
lower than in the healthy controls.
To study the response of each assay to a dose of oral thyroxine, blood samples
were taken from two of the controls at frequent intervals over a 48 hour period, a
single dose of oral thyroxine (0.3 mg) being taken after 24 hours (Figure 4). In this
preliminary study there was a stable baseline without evidence ofcircadian variation
for each of the three assays. Also there was no evidence that following oral
thyroxine, the free hormone rose out ofproportion to the bound fraction, nor that it
fell away more rapidly.
Free Thyroxine (pmol/1)
thyroxine 0.3 mg
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FIGURE 4
24 hour profiles ofFT4, TT4 and FT4I before and after 0.3 mg thyroxine in two
controlsubjects.
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,0DISCUSSION
This new FT4 assay accurately diagnosed clinical hyperthyroid and hypothyroid
states. Indeed hyperthyroid patients were very clearly differentiated from normal
controls. However, high FT4 readings were also obtained in clinically euthyroid
patients on thyroxine. Slightly elevated TT4 and FT41 have been found in treated
hypothyroid patients given enough thyroxine to normalise both baseline TSH2 and
the TSH response to thyrotropin releasing hormone.3 This may reflect a need for
relatively higher concentrations of exogenous thyroxine to compensate for the
failure of direct triiodothyronine production by the thyroid gland. Though in our
study, TT4 and FT4I were also elevated in euthyroid patients on thyroxine, the
distribution of these values above the upper limit of normal was less markedly
skewed than that of the FT4 values. In some patients on thyroxine (Table 2) FT4 was
TABLE 2
Clinically euthyroidpatients on thyroxine with high FT4 values
DIAGNOSIS AND FT4 TT4 FTI
THYROXINE DOSAGE (14.8-26,4pmol/I) (72-134 nmol/1) (67- 127)
HYPOPITUITARISM
0.2 mg
GOITRE
0.15 mg
HYPOPITUITARISM
0.2 mg
HYPOPITUITARISM
0.15 mg
HYPOTHYROIDISM FOLLOWING
THYROIDECTOMY
0.2 mg
HYPERTHYROIDISM
(ON PROPYLTHIOURACIL)
0.1 mg
HYPOPITUITARISM
0.1 mg
46.4
36.1
48.9
36.1
28.3
33.5
32.2
138
147
123
107
142
115
131
150
136
117
93
138
118
112
HYPOTHYROIDISM FOLLOWING
RADIOACTIVE IODINE
0.2 mg
HYPERTHYROIDISM
(ON NEOMERCAZOLE )
0.1 mg
46.4 168
36.1
171
167 147
91grossly elevated despite relatively normal TT4 and FT4I. Four of these patients were
on thyroxine replacement for hypopituitarism, therefore TSH would not be present
to aid assessment of dosage. Perhaps those patients with very high FT4 were truly
overtreated and the FT4 assay may detect such patients more easily. The 48 hour
profiles in two normal controls provided no evidence to suggest that the high FT4 in
patients on thyroxine was related to timing of dosage.
The actual value of FT4 in pregnancy is a matter of controversy.4 sUsing this
assay we obtained low values. It has been argued that a low FT4 in late pregnancy is
adequate to provide normal tissue levels in the presence ofvery high thyroid binding
protein concentrations.6 However, other FT4 assay kits give values similar to non-
pregnant controls.7
In non-thyroidal illness both thyroxine clearance and FT4 are generally considered
to be normal,8 though low TT4 is well recognised.9 We found low FT4 concentrations
perhaps because of unforeseen binding of the analogue to low affinity serum
proteins, which may be reduced in non-thyroidal illness. Normal values of FT4 have
beenreportedwithanumberofotherFT4radioimmunoassay kitsinthis situation.'°0"
Falsely high readings with this assay have been obtained in the rare condition of
familial euthyroid thyroxine excess'2 and also in the presence of antithyroxine
antibodies;'3 this is due to analogue binding to albumin and antibody respectively.
The concept that in euthyroid states FT4 levels lie within the normal range
irrespective of alterations in thyroid binding proteins is perhaps an over-
simplification. Circulating protein bound hormone does not just represent an inert
store, but is involved in the dynamics of tissue hormone supply. Thus the goal of a
single thyroid hormone test which reads within the same normal range in all
euthyroid states may be unattainable. Nevertheless tests which most nearly do this
will be easiest to interpret in clinical practice. In our study this appeared to be FT4I.
While results from the Amerlex free T4 assay may be of considerable value, those
using it as a screening test should be aware of the altered normal range in pregnancy
and non-thyroidal illness, and ofthe difficulties of interpreting results in patients on
thyroxine therapy.
SUMMARY
The clinical usefulness ofa free thyroxine (FT4) radioimmunoassay (Amerlex) was
compared with a total thyroxine (TT4) radioimmunoassay and with a derived free
thyroxine index (FT4I). In hyperthyroid patients FT4 gave a clearer separation from
normal than TT4 or FT4I. In 32 clinically euthyroid patients taking thyroxine, mean
values of all three tests were greater (p < 0.001) than in 53 clinically euthyroid
patients not taking thyroxine, although in five of the 32 on thyroxine, FT4 (but not
TT4 or FT4I) was grossly elevated. FT4 may detect overtreatment in apparently
euthyroid patients. In severely ill patients all three tests gave lower values (p<0.001)
than in controls. In euthyroid pregnancy FT4 was lower (p < 0.001) and TT4 higher
(p < 0.001) than in controls; FT4I in pregnancy was similar to controls. Clinicians
using the Amerlex free thyroxine assay should be aware of the altered range of
normality in pregnancy, non-thyroidal illness and in thyroxine treated patients.
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